Medpace schedules October 21 results: what it means for Medpace Holdings stock

Published on 10/20/2026 at 19:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mizuho kept Outperform on October 7, 2026. Medpace Holdings stock costs EUR 559.40 on October 20, 2026 at Lang & Schwarz after hours.

Reporting date and operating figures

Medpace Holdings will report third-quarter 2026 results after the market close on October 21, 2026.
Second-quarter revenue reached USD 707.33 million, up 17.20 percent year over year.
Medpace Holdings stock costs EUR 559.40 at Lang & Schwarz on October 20, 2026 at 7:16 p.m. CEST.

MEDP, US58506Q1094, Illustration mit AI erstellt.

Medpace Holdings (ISIN US58506Q1094) is scheduled to report third-quarter 2026 results after the market close on October 21, 2026. Medpace Holdings also scheduled its earnings call for October 22, 2026 at 9:00 a.m. ET. The stock was trading at EUR 559.40 at Lang & Schwarz on October 20, 2026 at 7:16 p.m. CEST.

Second-quarter growth sets the baseline

Medpace entered the reporting date with second-quarter revenue of USD 707.33 million, according to the Yahoo Finance transcript dated July 23, 2026. Revenue increased 17.20 percent from the second quarter of 2025, while net income rose 34.50 percent to USD 121.36 million and diluted earnings per share reached USD 4.25.

Operating profit was USD 146.82 million in the second quarter of 2026, producing a 20.76 percent operating margin. Operating cash flow reached USD 162.01 million in the same period, giving investors a second measure of execution beyond reported earnings.

What should investors compare?

The latest available Nasdaq quote was USD 629.23 on October 20, 2026 at 1:22 p.m. ET, with a market capitalization of USD 17.6 billion and a price-to-earnings ratio of 36.87. The primary-exchange 52-week range was USD 373.00 to USD 677.90 on October 20, 2026.

That valuation leaves the upcoming report with two measurable tests: whether revenue growth remains above the 17.20 percent second-quarter rate and whether profitability holds near the 20.76 percent operating margin. The company also employed approximately 6,500 people across 46 countries as of June 30, 2026.

Analyst view and reporting date

On October 7, 2026, Mizuho maintained an Outperform rating in a third-quarter earnings preview, as Markets Insider reported. The October 21 release and the October 22 conference call are the next scheduled company dates.

Stock position before results

Medpace operates as a full-service clinical research organization serving biotechnology, pharmaceutical and medical-device companies. Its next report will provide the next dated test of the revenue growth, margin and cash-flow figures established in the second quarter.

Medpace Holdings stock was trading at EUR 559.40 at Lang & Schwarz on October 20, 2026 at 7:16 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Medpace Holdings stock.